Skip to main content
SpringerLink
Log in
Book cover

Frühdiagnostik und Frühbehandlung psychischer Störungen pp 229–240Cite as

Ansätze zur Frühbehandlung bei degenerativen Hirnerkrankungen

  • Conference paper

  • 91 Accesses

Part of the book series: Bayer-ZNS-Symposium ((BAYERZNS,volume 13))

Zusammenfassung

Trotz eines besseren Verständnisses von Pathogenese und Pathophysiologie degenerativer Erkrankungen des Gehirns haben sich bislang kaum unmittelbare, klinisch nutzbare therapeutische Ansatzpunkte gezeigt. Die Effektivität einer pharmakologischen Frühbehandlung solcher Erkrankungen, insbesondere der Demenz vom Alzheimer-Typ (DAT) und des M. Parkinson, im Sinne einer Neuroprotektion ist weiterhin nicht eindeutig belegt. Vorbeugende Maßnahmen betreffen in erster Linie die Nahrungsmittelauswahl, bei der auf einen hohen Anteil an Radikalfängern, hauptsächlich Vitamin E, geachtet werden sollte. Bei M. Parkinson scheinen insbesondere MAO-B-Hemmer (Selegilin) und Amantadin den Krankheitsverlauf günstig beeinflussen zu können; jedoch ist die verlaufsbeeinflussende von einer symptomatischen Wirkung bisher nicht sicher abzugrenzen. Zur Frühbehandlung des M. Alzheimer kommen neben Selegilin, hochdosiertem Vitamin E und Gingko-biloba-Extrakt auch nichtsteroidale Antiphlogistika und eine Östrogensubstitution (bei Frauen) in Betracht; allerdings fehlen weiterhin aussagefähige Daten sowohl über den Zeitpunkt des Behandlungsbeginns als auch zur Wirkungs-Nebenwirkungs-Relation, so daß auch hier noch keine eindeutigen Empfehlungen möglich sind.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Albers GW, Atkinson RP, Kelley RE, Rosenbaum DM (1995) Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke. Stroke 26 (2): 254–258

    Article  PubMed  CAS  Google Scholar 

  • Anand R, Gharabawi G, Enz A (1996) Efficacy and safety results of the early phase studies with exelon(TM) (ENA-713) in Alzheimers disease — An overview. J Drug Dev Clin Pract 8 (2): 109–116

    CAS  Google Scholar 

  • Becker RE, Colliver JA, Markwell SJ, Moriearty PL, Unni LK, Vicari S (1996) Double-blind placebocontrolled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer disease. Alzheimer Dis Assoc Disord 10 (3): 124–131

    Article  PubMed  CAS  Google Scholar 

  • Behl C, Lezoualc, Trapp T, Widmann M, Skutella T, Holsboer F (1997). Glucocorticoids enhance oxidative stress-induced cell death in hippocampal neurons in vitro. Endocrinology 138 (1): 101–106

    Article  PubMed  CAS  Google Scholar 

  • Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, Shannon HE, Tollefson GD, Rasmussen K, Bymaster FP, et al. (1997) Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 54 (4): 465–473

    Article  PubMed  CAS  Google Scholar 

  • Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82 (4): 239–259

    Article  PubMed  CAS  Google Scholar 

  • Calne DB, Langston JW, Martin WR, Stoessl AJ, Ruth TJ, Adam MJ, Pate BD, Schulzer M (1985) Positron emission tomography after MPTP: observations relating to the cause of Parkinson’s disease. Nature 317 (6034): 246–248

    Article  PubMed  CAS  Google Scholar 

  • Chen HS, Pellegrini JW, Aggarwal SK, Lei SZ, Warach S, Jensen FE, Lipton SA (1992) Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J Neurosci 12 (11): 4427–4436

    PubMed  CAS  Google Scholar 

  • Cummings JL, Kaufer D (1996) Neuropsychiatric aspects of Alzheimers disease — The cholinergic hypothesis revisited. Neurology 47 (4): 876–883

    PubMed  CAS  Google Scholar 

  • Cummings J, Bieber F, Mas J, et al. (1997) Metrifonate in Alzheimer’s disease: Results of a dose-finding study. In: Iqbal K, Winblad B, Nishimura H, Takeda M, Wisniewski HM (eds) Alzheimer’s Disease: Biology, Diagnosis and Therapeutics. Wiley, Chichester, pp 665–669

    Google Scholar 

  • Davis KL, Powchik P (1995) Tacrine. Lancet 345 (8950): 625–630

    Article  PubMed  CAS  Google Scholar 

  • De Rijk MC, Breteler MB, Denbreeijen JH, Launer LJ, Grobbee DE, Vandermeche FA, Hofman A (1997) Dietary antioxidants and Parkinson disease — The Rotterdam study. Arch Neurol 54 (6): 762–765

    Article  PubMed  Google Scholar 

  • Eckols K, Bymaster FP, Mitch CH, Shannon HE, Ward JS, Delapp NW (1995) The muscarinic Ml agonist xanomeline increases soluble amyloid precursor protein release from Chinese hamster ovary-Ml cells. Life Sci 57 (12): 1183–1190

    Article  PubMed  CAS  Google Scholar 

  • Geerts H, Nuydens R, Dejong M, Cornelissen F, Nuyens R, Wouters L (1996) Sabeluzole stabilizes the neuronal cytoskeleton. Neurobiol of Aging 17 (4): 573–581

    Article  CAS  Google Scholar 

  • Graham JE, Rockwood K, Beattie BL, Eastwood R, Gauthier S, Tuokko H, McDowell I (1997) Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet 349: 1793–1796

    Article  PubMed  CAS  Google Scholar 

  • Gurwitz D, Haring R, Pinkaskramarski R, Stein R, Heldman E, Karton Y, Fisher A (1995) NGF-dependent neurotrophic-like effects of AF102B, an Ml muscarinic agonist, in PC12M1 cells. Neuroreport 6 (3): 485–488

    Article  PubMed  CAS  Google Scholar 

  • Heiss WD, Hebold I, Klinkhammer P, Ziffling P, Szelies B, Pawlik G, Herholz K (1988) Effect of piracetam on cerebral glucose metabolism in Alzheimer’s disease as measured by positron emission tomography. J Cereb Blood Flow Metab 8 (4): 613–617

    Article  PubMed  CAS  Google Scholar 

  • Heiss WD, Kessler J, Mielke R, Szelies B, Herholz K (1994) Long-term effects of phosphatidylserine, pyritinol, and cognitive training in Alzheimer’s disease. A neuropsychological, EEG, and PET investigation. Dementia 5 (2): 88–98

    PubMed  CAS  Google Scholar 

  • Hellenbrand W, Boeing H, Robra BP, Seidler A, Vieregge P, Nischan P, Joerg J, Oertel WH, Schneider E, Ulm G (1996a) Diet and Parkinson’s disease. II: A possible role for the past intake of specific nutrients. Results from a self-administered food-frequency questionnaire in a case-control study. Neurology 47 (3): 644–650

    PubMed  CAS  Google Scholar 

  • Hellenbrand W, Seidler A, Boeing H, Robra BP, Vieregge P, Nischan P, Joerg J, Oertel WH, Schneider E, Ulm G (1996b) Diet and Parkinson’s disease. I: A possible role for the past intake of specific foods and food groups. Results from a self-administered food-frequency questionnaire in a case-control study. Neurology 47 (3): 636–643

    PubMed  CAS  Google Scholar 

  • Hornykiewicz O (1966) Dopamine (3-hydroxytyramine) and brain function. Pharmacol Rev 18 (2): 925–964

    PubMed  CAS  Google Scholar 

  • Kaufmann WE, Worley PF, Pegg J, Bremer M, Isakson P (1996) COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc Natl Acad Sci USA 93 (6): 2317–2321

    Article  PubMed  CAS  Google Scholar 

  • Knopman D, Schneider L, Davis K, Talwalker S, Smith F, Hoover T, Gracon S (1996) Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality. Tacrine Study Group. Neurology 47 (1): 166–177

    PubMed  CAS  Google Scholar 

  • Koller WC, Montgomery EB (1997) Issues in the early diagnosis of Parkinsons-disease. Neurology 49 (Suppl 1): 10–25

    Google Scholar 

  • LeBars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF (1997) A placebocontrolled, double-blind randomized trial of an extract of ginkgo biloba for dementia. J Am Med Assoc 278 (16):1327–1332

    Article  CAS  Google Scholar 

  • Lees AJ (1995) Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson’s disease. Parkinson’s Disease Research Group of the United Kingdom. BMJ 311 (7020): 1602–1607

    Article  PubMed  CAS  Google Scholar 

  • Logroscino G, Marder K, Cote L, Tang MX, Shea S, Mayeux R (1996) Dietary lipids and antioxidants in Parkinson’s disease: a population-based, case-control study. Ann Neurol 39 (1): 89–94

    Article  PubMed  CAS  Google Scholar 

  • Maiese K, TenBroeke M, Kue I (1997) Neuroprotection of lubeluzole is mediated through the signal transduction pathways of nitric oxide. J Neurochem 68 (2): 710–714

    Article  PubMed  CAS  Google Scholar 

  • Marcusson J, Rother M, Kittner B, Rossner M, Smith RJ, Babic T, Folnegovicsmalc V, Möller HJ, Labs KH (1997) A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R. Dement Geriatr Cogn Disord 8 (5): 320–328

    Article  PubMed  CAS  Google Scholar 

  • Matsumoto T, Tsuda S, Nakamura S (1995) The neurotrophic effects of ebiratide, an analog of ACTH(4–9), on cultured septal cells and aged rats. J Neural Transm Gen Sect 100 (1): 1–15

    Article  PubMed  CAS  Google Scholar 

  • Mohr E, Nair NV, Sampson M, Murtha S, Belanger G, Pappas B, Mendis T (1997) Treatment of Alzheimers disease with sabeluzole — Functional and structural correlates. Clinical Neuropharmacology 20 (4): 338–345

    Article  PubMed  CAS  Google Scholar 

  • Morens DM, Grandinetti A, Waslien CI, Park CB, Ross GW, White LR (1996) Case-control study of idiopathic Parkinson’s disease and dietary vitamin E intake. Neurology 46 (5): 1270–1274

    PubMed  CAS  Google Scholar 

  • Muir KW, Grosset DG, Lees KR (1997) Effects of prolonged infusions of the NMDA antagonist aptiganel hydrochloride (CNS 1102) In normal volunteers. Clin Neuropharmacol 20 (4): 311–321

    Article  PubMed  CAS  Google Scholar 

  • Olanow CW (1997) Attempts to obtain neuroprotection in Parkinsons-disease. Neurology 49 (Suppl 1): 26– 33

    Google Scholar 

  • Paganini-Hill A, Henderson VW (1996) Estrogen replacement therapy and risk of Alzheimer disease. Arch Inter Med 156 (19):2213–2217.

    Article  CAS  Google Scholar 

  • Parkinson Study Group (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. The Parkinson Study Group. N Engl J Med 328 (3): 176–183

    Article  Google Scholar 

  • Parkinson Study Group (1996) Impact of deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP patients requiring levodopa. Parkinson Study Group. Ann Neurol 39 (1): 37–45

    Article  Google Scholar 

  • Pittel Z, Heldman E, Barg J, Haring R, Fisher A (1996) Muscarinic control of amyloid precursor protein secretion in rat cerebral cortex and cerebellum. Brain Res 742 (1–2): 299–304

    Article  PubMed  CAS  Google Scholar 

  • Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 276 (5321): 2045–2047

    Article  PubMed  CAS  Google Scholar 

  • Przedborski S, Jackson-Lewis V, Yokoyama R, Shibata T, Dawson VL, Dawson TM (1996) Role of neuronal nitric oxide in l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc Natl Acad Sci USA 93 (10): 4565–4571

    Article  PubMed  CAS  Google Scholar 

  • Przuntek H, Welzel D, Blumner E, Danielczyk W, Letzel H, Kaiser HJ, Kraus PH, Riederer P, Schwarzmann D, Wolf H (1992) Bromocriptine lessens the incidence of mortality in L-dopa-treated Parkinsonian patients: prado-study discontinued. Eur J Clin Pharmacol 43 (4): 357–363

    Article  PubMed  CAS  Google Scholar 

  • Przuntek H, Welzel D, Gerlach M, Blumner E, Danielczyk W, Kaiser HJ, Kraus PH, Letzel H, Riederer P, Überla K (1996) Early institution of bromocriptine in Parkinson’s disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study. J Neural Transm Gen Sect 103 (6): 699–715

    Article  CAS  Google Scholar 

  • Rainer M (1997) Clinical studies with galanthamine. Drugs of Today 33 (4): 273–279

    Article  CAS  Google Scholar 

  • Rockwood K, Beattie BL, Eastwood MR, Feldman H, Mohr E, Prysephillips, Gauthier S (1997) A randomized, controlled trial of linopirdine in the treatment of Alzheimers disease. Can J Neurol Sci 24 (2): 140–145

    PubMed  CAS  Google Scholar 

  • Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, Zalinski J, Cofield M, Mansukhani L, Willson P (1993) Clinical trial of indomethacin in Alzheimer’s disease. Neurology 43 (8): 1609–1611

    PubMed  CAS  Google Scholar 

  • Rogers SL, Friedhoff LT, Apter JT, Richter RW, Hartford JT, Walshe TM, Baumel B, Linden RD, Kinney FC, Doody RS, et al. (1996) The efficacy and safety of donepezil in patients with Alzheimers disease — Results of a multicentre, randomized, double-blind, placebo-controlled trial. Dementia 7 (6): 293–303

    PubMed  CAS  Google Scholar 

  • Sadot E, Gurwitz D, Barg J, Behar L, Ginzburg I, Fisher A (1996) Activation of M(l) muscarinic acetylcholine receptor regulates tau phosphorylation in transfected pcl2 cells. J Neurochem 66 (2): 877–880

    Article  PubMed  CAS  Google Scholar 

  • Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman DW, Pfeiffer E, et al. (1997) A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimers disease. N Engl J Med 336 (17): 1216–1222

    Article  PubMed  CAS  Google Scholar 

  • Secades JJ, Frontera G (1995) CDP-choline — Pharmacological and clinical review. Methods Find Exp Clin Pharmacol 17 (Suppl B): 1–54

    PubMed  CAS  Google Scholar 

  • Seidler A, Hellenbrand W, Robra BP, Vieregge P, Nischan P, Joerg J, Oertel WH, Ulm G, Schneider E (1996) Possible environmental, occupational, and other etiologic factors for Parkinson’s disease: a case-control study in Germany. Neurology 46 (5): 1275–1284

    PubMed  CAS  Google Scholar 

  • Snyder SH, D’Amato RJ (1985) Predicting Parkinson’s disease. Nature 317 (6034): 198–199

    Article  PubMed  CAS  Google Scholar 

  • Stewart WF, Kawas C, Corrada M, Metter EJ (1997) Risk of Alzheimer’s disease and duration of NSAID use. Neurology 48 (3): 626–632

    PubMed  CAS  Google Scholar 

  • Trojanowski JQ, Shin RW, Schmidt ML, Lee VM (1995) Relationship between plaques, tangles, and dystrophic processes in Alzheimer’s disease. Neurobiol Aging 16 (3): 335–340

    Article  PubMed  CAS  Google Scholar 

  • Uberti D, Rizzini C, Galli P, Pizzi M, Grilli M, Lesage A, Spano P, Memo M (1997) Priming of cultured neurons with sabeluzole results in long-lasting inhibition of neurotoxin-induced tau expression and cell death. Synapse 26 (2): 95–103

    Article  PubMed  CAS  Google Scholar 

  • Uitti RJ, Rajput AH, Ahlskog JE, Offord KP, Schroeder DR, Ho MM, Prasad M, Rajput A, Basran P (1996) Amantadine treatment is an independent predictor of improved survival in Parkinson’s disease. Neurology 46 (6):1551–1556

    PubMed  CAS  Google Scholar 

  • Vingerhoets FJ, Snow BJ, Lee CS, Schulzer M, Mak E, Calne DB (1994a) Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. Ann Neurol 36 (5): 759–764

    Article  PubMed  CAS  Google Scholar 

  • Vingerhoets FJ, Snow BJ, Tetrud JW, Langston JW, Schulzer M, Calne DB (1994b) Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions. Ann Neurol 36 (5):765–770

    Article  PubMed  CAS  Google Scholar 

  • Weyer G, Babejdolle RM, Hadler D, Hofmann S, Herrmann WM (1997) A controlled study of 2 doses of idebenone in the treatment of Alzheimers-disease. Neuropsychobiology 36 (2): 73–82

    Article  PubMed  CAS  Google Scholar 

  • Yamada K, Nitta A, Hasegawa T, Fuji K, Hiramatsu M, Kameyama T, Furukawa Y, Hayashi K, Nabeshima T (1997) Orally active ngf synthesis stimulators — Potential therapeutic agents in Alzheimers disease. Behav Brain Res 83 (1–2): 117–122

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. K. Herholz
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik und Poliklinik für Neurologie und Psychiatrie — Psychiatrie und Psychotherapie —, Universität zu Köln, Joseph-Stelzmann-Straße 9, 50924, Köln, Germany

    J. Klosterkötter

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Herholz, K. (1998). Ansätze zur Frühbehandlung bei degenerativen Hirnerkrankungen. In: Klosterkötter, J. (eds) Frühdiagnostik und Frühbehandlung psychischer Störungen. Bayer-ZNS-Symposium, vol 13. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-72204-2_23

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-72204-2_23

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-64440-8

  • Online ISBN: 978-3-642-72204-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation